Lung Cancer is the leading cause of cancer death worldwide. It is difficult to detect in its early stages, as well as understand and treat effectively.
Lung cancer R&D is experiencing rapid growth, representing an enormous opportunity for drug developers, with a 22% rise in new candidates in 2015.
The global market for Lung cancer therapeutics, currently valued at $5 billion is poised to reach $15.1 billion by 2023, expanding by a CAGR of 12%
Do You Have the Latest Insights to Transform the Success of Your Pipeline?
Precision: Lung Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations.
Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.
ANTIBODY DRUG CONJUGATES
Large Drug Developers
Small & Mid-Sized Developers
VP, Director, Head
GOALS OF THE EVENT
CSO & Co-Founder
Senior Director, Cell Biology
VP, Drug Discovery Biology
Chief Scientific Officer
Instructor in Medicine
Vice President, Oncology
Clinical Program Leader, Director
Director - Oncology Translational Science
Senior Scientist II - Biologics/Immunotherapy
VP, Translational Medicine
VIEW 2016 AGENDA
The Royal Sonesta Boston Hotel
40 Edwin H Land Blvd, Cambridge, MA 02142, USA
Copyright © 2017 | All content produced by: neo-synth ltd.